References
- SusserWSWhitaker-WorthDLGrant-KeisJMMucocutaneous reactions to chemotherapyJ Am Acad Dermatol199940336739810071309
- MinisiniAMTostiASobreroAFTaxane-induced nail changes: incidence, clinical presentation and outcomeAnn Oncol200214333337
- RobertCSibaudVMateusCNail toxicities induced by systemic chemotherapy treatmentsLancet Oncol2015164e181e19025846098
- PiracccineBMAlessandriniADrug-related nail diseaseClin Dermatol20135618626
- RosenACCaseECDuszaSWImpact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinicAm J Clin Dermatol20131432733323625802
- National Cancer Institute Cancer Therapy Evaluation Program [homepage on the Internet]Common Terminology Criteria for Adverse Events and Common Toxicity Criteria [v4.0]2010 Available from: http://www.oncology.tv/SymptomManagement/NationalCancerInstituteUpdatesCTCAEtov403.aspxAccessed April 8, 2017
- ParacciniBMIorizzoMStaraceMDrug-induced nail diseasesDermatol Clin20062438739116798438
- GuptaAParakhADubeyAPChemotherapy induced nail changesIndian J Dermatol200853420420519882038
- HussainSAndersonDNSalvattiMEOnycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literatureCancer200088102367237110820360
- ChenGChenYHsuMOnychomadesis and onycholysis associated with capecitabineBr J Dermatol2001145352152211531857
- SegaertSVan CutsemEClinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnn Oncol20051691425143316012181
- SpazzapanSCrivellariDLombardiDNail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?J Clin Oncol200220214404440512409345
- MortimerJJungJYuanYSkin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapyBreast Cancer Res Treat2014148356357025385180
- WantzinGLThomsenKAcute paronychia after high-dose methotrexate therapyArch Dermatol198311976236246859907
- HijjawiJBDennisonDGAcute felon as a complication of systemic paclitaxel therapy: case report and review of the literatureHand20072310110318780067
- CapriottiKCapriottiJATopical iodophor preparations: chemistry, microbiology, and clinical utilityDermatol Online J201218111
- BeukelmanCJvan den BergAJHoekstraMJAnti-inflammatory properties of a liposomal hydrogel with povidoneiodine (Repithel®) for wound healing in vitroBurns20083484585518378399
- SchwarzHABielskiBHJReactions of HO2 and O2− with iodine and bromine and the I2− and I atom reduction potentialsJ Phys Chem19869014451448
- CapriottiKCapriottiJADimethyl sulfoxide: history, chemistry, and clinical utility in dermatologyJ Clin Aesthet Dermatol2012592426
- CapriottiKCapriottiJALessinSThe risk of nail changes with taxane chemotherapy: a systemic review of the literature and meta-analysisBr J Dermatol2015173384284525704465
- GardenBCWuSLacoutureMEThe risk of nail changes with Epidermal Growth Factor Receptor InhibitorsJ Am Acad Dermatol201267340040822088429
- WasnerGHilpertFSchattschneiderJBinderAPfistererJBaronRDocetaxel-induced nail changes – a neurogenic mechanism: a case reportJ Neurooncol200258216717412164689
- WasnerGHilpertFBaronRPfistererJClinical picture: nail changes secondary to docetaxelLancet2001357926091011289346
- GhettiEPiracciniBMTostiAOnycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel)J Europ Acad Dermtol Venereol2003174459460
- PhamAQBerzDKarwanPColvinGACremophor-induced lupus erythematosus-like reaction with taxol administration: a case report and review of the literatureCase Rep Oncol20114352653022125524
- TokunagaMIgaNEndoYElevated protoporphyrin in patients with skin cancer receiving taxane chemotherapyEur J Dermatol201323682682924480579
- BragadoRBelloERequenaLIncreased expression of vascular endothelial growth factor in pyogenic granulomasActa Derm Venereol19997942242510598753